CDMO Frontida Strengthens Quality Operations

Frontida BioPharm, Inc., a minority-owned contract development and manufacturing organization (CDMO), has appointed Steven Roese as Vice President of Quality. Mr. Roese joins Frontida with over 25 years of experience in quality operations and pharmaceutical industry management.

“Steven’s experience in multi-site quality organization achievements is an invaluable asset to Frontida’s operational contributions,” said Anthony Qu, chief operating officer, Frontida. “His demonstrated history of commitment to improving procedural effectiveness and achieving product quality improvements will undoubtedly help Frontida surpass both current and new milestones.”

Mr. Roese’s professional engagement within the pharmaceutical industry features proven excellence in the management of GMP operations, compliance, quality systems, GCP/GLP oversights, and product manufacturing. In addition, he has overseen the successful launch of commercial drug products and development of clinical trial programs. Effective immediately, Mr. Roese will be responsible for Frontida’s performance metrics, system audit standards, quality assurance and quality control operations.

Renard Jackson, Frontida’s executive vice president of contract operations, said, “The Frontida team is very pleased to have Steve Roese join us as the new vice president of quality. His diverse quality background and global experience will provide the required quality leadership during this strong growth phase, while maintaining a continuous improvement mindset.”

Frontida BioPharm, Inc. is a U.S. based, minority-owned CDMO providing drug delivery technologies, product development, and manufacturing services for pharmaceutical and consumer health companies. It supports pharmaceutical companies in the development, scale-up and commercial manufacturing of immediate and controlled-release oral solid dose, powder and liquid products; ensuring robust product performance and on-time supply of clinical trial materials and commercial products.

From its 325,000+ sq. ft. manufacturing facilities located in Philadelphia, PA and Aurora, IL, Frontida offers a comprehensive suite of solutions for the development and commercialization of prescription, OTC, highly potent active compounds, Phase I through Phase III clinical trial materials, fixed-dose combination products and DEA schedule II – V products.

In addition, Frontida is equipped with multiple commercial packaging lines, capable of validated product serialization, and providing packaging services for both commercial products and clinical trial material supplies in bottles and blisters. The CDMO has an annual capacity to manufacture up to 3 billion tablets and capsules.